谷维素
- 主题发起人 bigboy888
- 开始时间
- 注册
- 2006-09-30
- 消息
- 14,407
- 荣誉分数
- 94
- 声望点数
- 0
oryzanol
Drug Name
oryzanol
World Status
Discontinued
Pharma Status
Ceased
N-gamma-oryzanol
N-gamma-oz
Latest Change
Updated On By Latest Change
9 Nov 1989 UN Not updated since latest change field introduced
Company Status Data
Originator Country Development Stage
Zeria Japan Discontinued
Activity Data
Therapy Description Code Status
Hypolipaemic/Antiatherosclerosis C10 Discontinued
Pharmacology Description Code
Cholesterol antagonist CHOL-
Therapy Code Pharmacology Code
C10 CHOL-
Chemical Data
CAS Registry Number Molecular Weight Molecular Formula
12738-23-7
Chemical Name
Oryzanol [CAS]
Country Data
Country Name Status Year Launched Licensing Op.
Argentina - No
Australia - No
Austria - No
Belgium - No
Brazil - No
Canada - No
Chile - No
China - No
Colombia - No
Denmark - No
Finland - No
France - No
Germany - No
Greece - No
Hong Kong - No
India - No
Ireland - No
Israel - No
Italy - No
Japan Phase II Clinical Trial No
Luxembourg - No
Malaysia - No
Mexico - No
Netherlands - No
New Zealand - No
Norway - No
Peru - No
Philippines - No
Portugal - No
Russian Federation - No
South Africa - No
South Korea - No
Spain - No
Sweden - No
Switzerland - No
Thailand - No
Turkey - No
UK - No
USA - No
Venezuela - No
Major Events
Event Date Act/Est Event Details
15 Jun 1989 Est Discontinued Products
Ratings
Novelty Market Size Speed Total
Not available (0) US$ 5001-10000 million (4) Not available (0) Not available
Detailed Information
Zeria has discontinued development of oryzanol, a hypolipaemic (Company communication, Mar 1989). It had been in Phase II clinical trials. In rats given 100, 500 or 1000mg/kg po oryzanol for 6 or 12 days there was no effect on liver serum total cholesterol, triglycerides and phospholipids. Diet-induced decreases in HDL were only inhibited by the 12 day therapy. Increased triglyceride levels were inhibited after 6 days of therapy at all doses and after 12 days at 500 and 1000mg/kg. Doses of 500mg/kg or 1000mg/kg oryzanol for 12 days reduced the atherogenic index based on serum total cholesterol and phospholipids, respectively (Jpn J Pharmacol, 1987, 44, 135). In 81 patients with hypercholesterolaemia, 300mg/day for 12wk decreased total serum cholesterol by 12%, LDL-cholesterol by 15%, apolipoprotein-B by 13%, lipid peroxide by 34% and serum triglyceride by 21% (8th Int Symp Atherosclerosis (Rome), 1988, p48, 1056).
Drug Name
oryzanol
World Status
Discontinued
Pharma Status
Ceased
N-gamma-oryzanol
N-gamma-oz
Latest Change
Updated On By Latest Change
9 Nov 1989 UN Not updated since latest change field introduced
Company Status Data
Originator Country Development Stage
Zeria Japan Discontinued
Activity Data
Therapy Description Code Status
Hypolipaemic/Antiatherosclerosis C10 Discontinued
Pharmacology Description Code
Cholesterol antagonist CHOL-
Therapy Code Pharmacology Code
C10 CHOL-
Chemical Data
CAS Registry Number Molecular Weight Molecular Formula
12738-23-7
Chemical Name
Oryzanol [CAS]
Country Data
Country Name Status Year Launched Licensing Op.
Argentina - No
Australia - No
Austria - No
Belgium - No
Brazil - No
Canada - No
Chile - No
China - No
Colombia - No
Denmark - No
Finland - No
France - No
Germany - No
Greece - No
Hong Kong - No
India - No
Ireland - No
Israel - No
Italy - No
Japan Phase II Clinical Trial No
Luxembourg - No
Malaysia - No
Mexico - No
Netherlands - No
New Zealand - No
Norway - No
Peru - No
Philippines - No
Portugal - No
Russian Federation - No
South Africa - No
South Korea - No
Spain - No
Sweden - No
Switzerland - No
Thailand - No
Turkey - No
UK - No
USA - No
Venezuela - No
Major Events
Event Date Act/Est Event Details
15 Jun 1989 Est Discontinued Products
Ratings
Novelty Market Size Speed Total
Not available (0) US$ 5001-10000 million (4) Not available (0) Not available
Detailed Information
Zeria has discontinued development of oryzanol, a hypolipaemic (Company communication, Mar 1989). It had been in Phase II clinical trials. In rats given 100, 500 or 1000mg/kg po oryzanol for 6 or 12 days there was no effect on liver serum total cholesterol, triglycerides and phospholipids. Diet-induced decreases in HDL were only inhibited by the 12 day therapy. Increased triglyceride levels were inhibited after 6 days of therapy at all doses and after 12 days at 500 and 1000mg/kg. Doses of 500mg/kg or 1000mg/kg oryzanol for 12 days reduced the atherogenic index based on serum total cholesterol and phospholipids, respectively (Jpn J Pharmacol, 1987, 44, 135). In 81 patients with hypercholesterolaemia, 300mg/day for 12wk decreased total serum cholesterol by 12%, LDL-cholesterol by 15%, apolipoprotein-B by 13%, lipid peroxide by 34% and serum triglyceride by 21% (8th Int Symp Atherosclerosis (Rome), 1988, p48, 1056).
- 注册
- 2003-08-23
- 消息
- 1,296
- 荣誉分数
- 37
- 声望点数
- 208
